Abstract
Background Current methods of COVID-19 detection from other respiratory illnesses using computed tomography (CT) scans are highly inaccurate. However, understanding pathogen-specific immune responses can help reduce inconsistencies and improve the accuracy of COVID-19 and Pneumonia detection. A deep learning model using Relief-based feature selection (RBAs) was developed to detect COVID-19 and Pneumonia. Patient-specific Class Activation Maps (CAMs) were produced to highlight immunopathogenic differences and identify differences between COVID-19 and Pneumonia on CT scans.
Methods To examine the effect on lung lesions, a COVIDx CT-2 dataset, containing CT scans from 3,745 patients, was examined. We developed an algorithm to convert the 3-D CT scan of each patient into multiple 2-D slices. Altogether, there were 194,344 2-D slices retrieved from 3,745 CT Scans. The distribution of slices was 67%-20%-17% consisting of COVID-19, Pneumonia, and normal CT scan, respectively. An AlexNet architecture was implemented with additional feature extraction layers (containing RBA) and classification layers to perform deep learning. The 2-D slices were divided into 3 groups: Training, Test, and Validation. The training set consisted of 70% of the data, the test set consisted of 20% of the data, and the validation consisted of 10% of the data. After training, unique CAMs were generated on patient CT scans using the immunopathogenic differences to highlight COVID-19 and Pneumonia related abnormalities.
Results The model accurately distinguished hyperinflammation in COVID-19 patients from Pneumonia patients and achieved a validation accuracy of 95.60% and a false-positive rate of 4.65%. Additionally, the segmented lung, shown by the patient-specific CAMs, identified higher levels of inflammation in the lung of COVID scans compared to the other two groups.
Discussion The use of deep learning in disease diagnosis and prevention has provided many avenues to advance current techniques. Likewise, in this analysis, deep learning was shown to successfully predict COVID-19 via CT scan. By providing patient-specific CAMs, the model can be used to not just aid in diagnosis but potentially also to evaluate serial chest CT scans for treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding supported this work. HTK was supported by NIMH K01MH122741.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.kaggle.com/datasets/hgunraj/covidxct
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest. The authors declare no conflicts of interest.
Funding. No funding supported this work. HTK was supported by NIMH K01MH122741.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.